Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer

被引:0
|
作者
Capuozzo, Maurizio [1 ]
Santorsola, Mariachiara [2 ]
Ianniello, Monica [3 ]
Ferrara, Francesco [1 ]
Zovi, Andrea [4 ]
Petrillo, Nadia [3 ]
Castiello, Rosa [3 ]
Fantuz, Maria Rosaria [3 ]
Ottaiano, Alessandro [2 ]
Savarese, Giovanni [3 ]
机构
[1] ASL Naples 3, Coordinamento Farmaceut, I-80056 Ercolano, Italy
[2] IRCCS G Pascale, Ist Nazl Tumori Napoli, Via M Semmola, I-80131 Naples, Italy
[3] Ctr Polidiagnost Strumentale Srl, AMES, Via Padre Carmine Fico 24, I-80013 Casalnuovo Di Napoli, Italy
[4] Minist Hlth, Viale Giorgio Ribotta 5, I-00144 Rome, Italy
关键词
prostate cancer; androgen-deprivation therapy; immunotherapy; PARP inhibitors; precision medicine; PHASE-III TRIAL; SIPULEUCEL-T; DOUBLE-BLIND; PLUS STANDARD; OPEN-LABEL; CASTRATION; IPILIMUMAB; IMMUNOTHERAPY; ENZALUTAMIDE; MULTICENTER;
D O I
10.3390/diseases12050087
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
    Bahmad, Hisham F.
    Demus, Timothy
    Moubarak, Maya M.
    Daher, Darine
    Moreno, Juan Carlos Alvarez
    Polit, Francesca
    Lopez, Olga
    Merhe, Ali
    Abou-Kheir, Wassim
    Nieder, Alan M.
    Poppiti, Robert
    Omarzai, Yumna
    MEDICAL SCIENCES, 2022, 10 (01)
  • [22] Nanomedicine for the Treatment of Advanced Prostate Cancer
    Vicente-Ruiz, Sonia
    Serrano-Marti, Antoni
    Arminan, Ana
    Vicent, Maria J.
    ADVANCED THERAPEUTICS, 2021, 4 (01)
  • [23] ADVANCED CANCER OF THE PROSTATE - METHODS OF TREATMENT
    FAUL, P
    ALTWEIN, JE
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1984, 109 (51-5) : 1975 - 1980
  • [24] TREATMENT OF ADVANCED PROSTATE-CANCER
    PERRIN, P
    LYON CHIRURGICAL, 1987, 83 (01) : 71 - 71
  • [25] Treatment of locally advanced prostate cancer
    Wirth, MP
    Hakenberg, OW
    Fröhner, M
    UROLOGE, 2005, 44 (11): : 1295 - 1302
  • [26] Systemic treatment of advanced prostate cancer
    Kretschmer, Alexander
    Todenhoefer, Tilman
    UROLOGE, 2020, 59 (12): : 1565 - 1576
  • [27] Current Treatment of advanced Prostate Cancer
    Gratzke, Christian
    Stief, Christian G.
    UROLOGE, 2017, 56 (11): : 1381 - 1382
  • [28] TREATMENT OF ADVANCED PROSTATE-CANCER
    BISHOP, MC
    LANCET, 1994, 343 (8889): : 110 - 111
  • [29] Improving Treatment for Advanced Prostate Cancer
    Tannock, Ian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02): : 176 - 177
  • [30] Immunotherapy in the treatment of advanced prostate cancer
    Djavan, Bob
    Nelson, Kathleen
    Kazzazi, Amir
    Bruhn, Aron
    Sadri, Helen
    Gomez-Pinillos, Alejandro
    Ferrari, Anna C.
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (05) : 5865 - 5874